Detalles de la búsqueda
1.
A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection.
Ann Surg Oncol
; 19(2): 597-604, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21732142
2.
Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer.
Oncology
; 79(3-4): 197-203, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21358207
3.
Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer.
Oncology
; 79(3-4): 204-10, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21358208
4.
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
J Clin Oncol
; 29(2): 242-8, 2011 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-21115872
5.
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
J Clin Oncol
; 28(9): 1473-80, 2010 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-20177030
6.
Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Oncology
; 70(2): 141-6, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16645327
7.
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
Ann Surg Oncol
; 13(12): 1702-10, 2006 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17009163
Resultados
1 -
7
de 7
1
Próxima >
>>